Technical Analysis for CKPT - Checkpoint Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 3.51 | 2.03% | 0.07 |
Earnings due: Nov 11
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Slingshot Bullish | Bullish Swing Setup | 2.03% | |
| Wide Bands | Range Expansion | 2.03% | |
| Overbought Stochastic | Strength | 2.03% | |
| Volume Surge | Other | -3.04% | |
| New 52 Week High | Strength | -3.04% | |
| Upper Bollinger Band Walk | Strength | -3.04% | |
| Wide Bands | Range Expansion | -3.04% |
| Alert | Time |
|---|---|
| Possible NR7 | about 18 hours ago |
| Possible Inside Day | about 18 hours ago |
| 60 Minute Opening Range Breakout | about 21 hours ago |
| Rose Above 10 DMA | about 21 hours ago |
| Up 2% | about 21 hours ago |
Get a Trading Assistant
- Earnings date: 11/11/2024
Checkpoint Therapeutics, Inc. Description
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Immune System Antibodies Cancer Immunotherapy Chemotherapy Epidermal Growth Factor Receptor Solid Tumor Cancers Immune Checkpoint Checkpoint Inhibitor Necrosis Tumor Necrosis Factor Immuno Oncology Biopharmaceutical Tumor Necrosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.97 |
| 52 Week Low | 1.36 |
| Average Volume | 649,635 |
| 200-Day Moving Average | 2.13 |
| 50-Day Moving Average | 2.57 |
| 20-Day Moving Average | 3.04 |
| 10-Day Moving Average | 3.50 |
| Average True Range | 0.24 |
| RSI (14) | 67.85 |
| ADX | 51.18 |
| +DI | 28.45 |
| -DI | 9.54 |
| Chandelier Exit (Long, 3 ATRs) | 3.25 |
| Chandelier Exit (Short, 3 ATRs) | 2.88 |
| Upper Bollinger Bands | 4.05 |
| Lower Bollinger Band | 2.04 |
| Percent B (%b) | 0.73 |
| BandWidth | 66.21 |
| MACD Line | 0.33 |
| MACD Signal Line | 0.30 |
| MACD Histogram | 0.037 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.73 | ||||
| Resistance 3 (R3) | 3.71 | 3.62 | 3.69 | ||
| Resistance 2 (R2) | 3.62 | 3.56 | 3.63 | 3.68 | |
| Resistance 1 (R1) | 3.57 | 3.53 | 3.59 | 3.58 | 3.67 |
| Pivot Point | 3.47 | 3.47 | 3.49 | 3.48 | 3.47 |
| Support 1 (S1) | 3.42 | 3.42 | 3.45 | 3.44 | 3.35 |
| Support 2 (S2) | 3.33 | 3.39 | 3.34 | 3.34 | |
| Support 3 (S3) | 3.27 | 3.33 | 3.33 | ||
| Support 4 (S4) | 3.29 |
